
MaxCyte, Inc.
- Jurisdiction
United States - LEI
54930053YHXULRFCU991 - ISIN
US57777K1060 (MXCT )- Sectors
Scores
- Fair value (Benjamin Graham formula)
- N/A
- Financial strength (Piotroski F-Value)
-
2
/ 9
- Fundamental strength relative to industry (Mohanram G-Value)
-
3
/ 7
Profile
MaxCyte, Inc., a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Read full profile
Stock price
Fundamentals
- Net revenue
€30.69M - Gross margin
76.8% - EBIT
-€45.02M - EBIT margin
-146.7% - Net income
-€38.43M - Net margin
-125.2%
Statement period: - (published )
Estimates
Fiscal Year | Net revenue | Net income |
---|---|---|
|
| |
|
| |
|
|
Dividends
No dividend payouts
Insider Transactions
Name | Title | Transaction Date | Shares | Price | Value |
---|---|---|---|---|---|
Brooke William W | N/A |
|
|
|
|
DOUGLAS RICHARD | N/A |
|
|
|
|
Erck Stanley C | N/A |
|
|
|
|
Masoud Maher | President and CEO |
|
|
|
|
Swirsky Douglas J | CHIEF FINANCIAL OFFICER |
|
|
|
|
Earnings Calls
Latest earnings call: May 11, 2024
Investor transactions
Name | Shares | Value | Last change | Change type |
---|---|---|---|---|
Peter Brown |
|
|
|
Buy |